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Purpose: To investigate to what degree the presence of hypertension (HTN) and poor glycemic 
control (GC) influences the likelihood of having microalbuminuria (MAU) among Cuban 
Americans with type 2 diabetes (T2D).
Methods: A cross-sectional study conducted in Cuban Americans (n = 179) with T2D. 
Participants were recruited from a randomly generated mailing list purchased from Knowledge-
Base Marketing, Inc. Blood pressure (BP) was measured twice and averaged using an adult 
size cuff. Glycosylated hemoglobin (A1c) levels were measured from whole blood samples 
with the Roche Tina-quant method. First morning urine samples were collected from each 
participant to determine MAU by a semiquantitative assay (ImmunoDip).
Results: MAU was present in 26% of Cuban Americans with T2D. A significantly higher per-
centage of subjects with MA had HTN (P = 0.038) and elevated A1C (P = 0.002) than those with 
normoalbuminuria. Logistic regression analysis showed that after controlling for covariates, 
subjects with poor GC were 6.76 times more likely to have MAU if they had hypertension com-
pared with those without hypertension (P = 0.004; 95% confidence interval [CI]: 1.83, 23.05). 
Conclusion: The clinical significance of these findings emphasizes the early detection of MAU 
in this Hispanic subgroup combined with BP and good GC, which are fundamentals in prevent-
ing and treating diabetes complications and improving individuals’ renal and cardiovascular 
outcomes.
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Introduction
In past years, numerous studies have described the role of microalbuminuria (MAU) 
as a predictor of cardiovascular disease (CVD) and death among subjects with 
type 2 diabetes (T2D).1–3 MAU is one of the earliest clinical signs for diabetic 
  nephropathy and a significant risk factor for progression to proteinuria.1 Additionally, 
hypertensive T2D individuals with MAU have an increased risk of developing end-
stage renal disease (ESRD).4 Risk factors known to be associated with CVD and 
diabetic nephropathy are high blood pressure (BP) and elevated glycosylated 
hemoglobin (A1c).5,6 Achieving adequate BP and glycemic control (GC) plays an 
essential role in preventing renal and CVD events in individuals with T2D.
A current secondary analysis from the Hispanic Health and Nutritional Examina-
tion Survey (HHANES)7 indicated that Cuban Americans have higher serum cholesterol 
and systolic BP than Puerto Ricans and Mexican Americans. Furthermore, compared 
with other Hispanic subgroups, Cuban Americans have the highest proportion of 
hypertension (HTN) and mean serum creatinine levels.8 Smith and Barnett9 examined International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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the National Center for Health Statistics (NCHS) from 1996 
to 1997 and concluded that Cuban Americans 35 years of 
age and older have the highest percentage of diabetes-related 
deaths compared with other Hispanics.
Although previous studies have shown significant 
differences and diversity within Hispanics, further studies 
conducted in the Cuban American population are scarce. 
Over the past decade, the prevalence of T2D has increased, 
especially among Cuban Americans who have a higher inci-
dence of diabetes (8.2%) compared with 6.6% of non-Hispanic 
Whites.10 The high incidence of T2D combined with an 
increased risk for developing diabetes complications warrants 
further examination of the Cuban American population. 
Screening for MAU can detect individuals at risk for renal 
dysfunction and CVD events and possibly reduce the burden 
associated with diabetes complications. Therefore, the pur-
pose of this study was to investigate to what degree the 
coexistence of HTN and poor GC influences the likelihood 
of having MAU among Cuban Americans with T2D. It was 
hypothesized that individuals with T2D, HTN, and poor GC 
will have an increased likelihood to test positive for MAU. It 
was further hypothesized that this association will be stronger 
after controlling for confounding variables.
Methods
Design
This was a cross-sectional study conducted in Cuban 
Americans with and without T2D.
study population
Data from a complete sample set of Cuban Americans with 
and without T2D were used in the present study. Recruitment 
of participants was conducted in alternate phases of poten-
tial subjects with and without T2D, age matching subjects by 
age groups. During a 1-year period, approximately 
10,000 letters outlining the study were mailed to subjects aged 
30 years or older with and without diabetes. Letters were sent 
in English and Spanish and included an invitation flyer to 
which interested participants could respond. The participants 
were initially recruited by random selection (every tenth 
address) from a randomly generated mailing list. The list of 
addresses was purchased from KnowledgeBase Marketing, 
Inc., Richardson, TX, USA. This company provided a mailing 
list of Cuban Americans identified as with and without T2D 
from Miami-Dade and Broward Counties, Florida. Three 
percent (n = 300) of the letters were returned due to unknown 
addresses. From the remaining delivered mail, 4% (n = 388) 
responded. Interested participants were initially interviewed 
on the phone, at which time the study purpose was explained 
and the age and gender of the responders were determined. 
To ascertain T2D status, each participant was asked for the 
age of diagnosis and initial treatment modalities. Only 
18 subjects did not qualify for the study for not being Cuban 
Americans (n = 2), age younger than 30 years (n = 9), and 
having other chronic illnesses (n = 7). If a subject was deter-
mined to be eligible, then their participation was requested at 
the Human Nutrition Laboratory at Florida International 
University (FIU). Participants were instructed to refrain from 
smoking, consuming any food and beverages except water, 
and doing any unusual exercise for at least 8 hours prior to 
their blood collection. Subjects with T2D were matched for 
age and gender with subjects without diabetes. This study 
was approved by the Institutional Review Board at FIU. The 
purpose and protocol of the study were explained to the sub-
jects, and their written consent, either in Spanish or English, 
was obtained prior to the commencement of the study. Seven 
participants reported not having diabetes but were reclassified 
because their lab results classified them as having T2D 
according to American Diabetes Association (ADA) stan-
dards. These subjects were given their laboratory results and 
referred to their physicians. For the data analysis, subjects 
with caloric intakes .5000 kcals (n = 2) and missing A1c 
levels (n = 2) were excluded. For two participants, we were 
unable to perform A1c analysis. In total, we included only 
the data from subjects with T2D (n = 179) who were aged 
30 years and older.
study variables
A sociodemographic questionnaire was given to each 
participant to complete, which included questions related to 
age, gender, smoking status, medications for diabetes, HTN, 
and cholesterol. Height and weight were measured using a 
Seca balance scale (Seca Corp, Columbia, MD, USA). Body 
mass index (BMI) was calculated as weight in kg/height in 
m2. BP was measured twice then averaged in participants in 
a sitting position after a 15-minute rest using a random zero 
sphygmomanometer (Tycos 5090-02 Welch Allyn Pocket 
Aneroid Sphygmomanometer, Arden, NC, USA) and a 
stethoscope (Littmann Cardiology, 3M, St Paul, MN, USA). 
HTN was defined as follows: systolic BP $ 140 mm Hg systolic 
or diastolic BP $ 90 mm Hg or using antihypertensive 
treatment.11
Dietary assessment
Dietary intake was measured using a validated semiquantita-
tive food frequency questionnaire (FFQ) developed by International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Willett et al.12 This FFQ has also been validated by Nath 
and Huffman13 exclusively for the Cuban American popula-
tion. Participants self-reported average consumption of speci-
fied amounts of various foods over the past year and chose 
from frequency responses ranging from “never” to “six or 
more servings per day”. In addition to food items, the FFQ 
included questions about type and duration of vitamin/mineral 
supplement use, alcohol consumption, and specific details 
about fat, salt, and sugar used in cooking and as condiments. 
Macro- and micronutrient intake was calculated by multiply-
ing frequency of consumption by the nutrient value of the 
food item obtained from the Harvard University Food Com-
position Database (Boston, MA, USA).
Blood collection
Venous blood (20 mL) was collected from each subject after an 
overnight fast (at least 8 hours) by a certified phlebotomist using 
standard laboratory techniques. Blood samples were collected 
into a Vacutainer® Serum Separator Tube (SST) (Becton, Dick-
inson and Company, Franklin Lakes, NJ) for analysis of lipids 
and another tube containing ethylenediamine tetraacetic acid to 
analyze A1c. After coagulation was completed (30–45 minutes), 
the SST was centrifuged at 2500 RPM for 30 minutes. Lipid 
panel was assayed by enzymatic methods, and A1c percentages 
were measured from whole blood samples with the Roche Tina-
quant method by Laboratory Corporation of America, Miami, 
FL, USA (LabCorp®). Poor GC was defined according to the 
ADA standards (A1c . 7%).14
Urinary albumin
Fresh, single-voided, first morning urine samples were col-
lected from each participant to determine MAU by a semi-
quantitative assay (ImmunoDip, Diagnostic Chemicals 
Limited, Oxford, CT, USA). ImmunoDip Urinary Albumin 
Test uses a monoclonal antibody against human serum albu-
min to detect MAU. The study conducted by Davidson et al15 
was designed to evaluate the clinical performance of 
the ImmunoDip dipstick compared with a reference 
measure recommended by the ADA for detecting MAU 
(albumin:creatinine ratio ,30 ug/mg [negative]; .30 ug/mg 
[positive]) determined by laboratory techniques (Quest 
Hitachi 717 autoanalyzer). Additionally, results from the 
ImmunoDip were compared with quantitatively measured 
albumin concentrations as a secondary outcome. Urinary 
albumin concentrations were considered ,18 mg/L (nega-
tive) and .18 mg/L (positive). Screening for MAU with 
ImmunoDip exhibited a sensitivity of 96% and specificity of 
80% when compared with albumin:creatinine ratio .30 ug/mg. 
When ImmunoDip was examined against quantitatively 
measured albumin concentrations, the dipstick yielded a 
sensitivity of 95% and specificity of 94%. Recommendations 
from the National Academy of Clinical Biochemistry 
(NACB) for the diagnosis and management of diabetes indi-
cated that a useful semiquantitative screening test for MAU 
should have a sensitivity .95%.16 The ImmunoDip dipstick 
fulfilled the requirements from the NACB as a screening tool 
to detect MAU. In our study, positive for MAU was defined 
as urinary albumin concentrations of .18 mg/L in spot col-
lection. This cut-off value was established by the manufac-
turer (ImmunoDip, Diagnostic Chemicals Ltd) and 
corresponded to albumin:creatinine ratio .30 ug/mg values 
for MAU detection.15
Data analysis
All analyses were performed using SPSS Version 17 
(SPSS Inc., Chicago, IL, USA). T-tests and Chi-square tests 
were performed to compare means and proportion differ-
ences between subjects with and without MAU. Unadjusted 
odds ratios and logistic regression analysis were conducted 
to investigate the extent to which HTN and GC are associ-
ated with an increased likelihood of having MAU. 
Controlled variables included in the logistic regression 
analysis were age, gender, BMI, known duration of 
  diabetes, total cholesterol levels, diabetes and cholesterol 
medications, smoking, total kcal and protein intake, and 
intake of potassium, phosphorous, and sodium. The level 
of significance was set at P , 0.05.
Results
MAU was present in 26% (n = 47) of Cuban Americans 
with T2D. There was a significantly higher percentage of 
subjects with MAU classified as hypertensive (P = 0.038) 
and taking diabetes medication (P = 0.039) compared with 
those without MAU. Additionally, subjects who tested 
positive for MAU had significantly higher A1c levels 
(P  =  0.002)  than  those  with  normoalbuminuria 
(Table 1).
Unadjusted odds ratios indicated that subjects with poor 
GC were 3.96 times more likely to have positive MAU if 
they had HTN compared with those without HTN 
(P = 0.014; 95% confidence interval [CI] 1.25, 12.5) 
(Figure 1). Logistic regression analysis showed that after 
controlling for covariates, subjects with poor GC were 
6.76 times more likely to have MAU if they had HTN 
compared with those without HTN (P = 0.004; 95% CI 
1.83, 23.05) (Table 2).International Journal of Nephrology and Renovascular Disease 2011:4
Table 1 characteristics of subjectsa
Cuban Americans with type 2 diabetes P value
Microalbuminuria
Positive  
(n = 47)
Negative  
(n = 132)
gender (female/male) (%) 53.2/46.8 64.4/35.6 0.175
Age (years) 67.9 ± 12.9 64.4 ± 11.4 0.083
Body mass index (kg/m2) 30.5 ± 6.0 31.9 ± 6.7 0.219
Waist circumference (cm) 105.7 ± 15.0 105.4 ± 14.6 0.892
smoking (%) 17.0 14.4 0.666
Known duration of diabetes (years) 10.5 ± 10.1 8.9 ± 9.5 0.338
Diabetes medications (%) 89.4 75 0.039
glycosylated hemoglobin (%) 8.2 ± 2.0 7.4 ± 1.5 0.002
hypertension medications (%) 61.7 52.3 0.265
systolic blood pressure (mm hg) 133.69 ± 14.5 131.48 ± 15.6 0.399
Diastolic blood pressure (mm hg) 78.3 ± 9.9 80.1 ± 8.4 0.225
hypertension (%) 78.7 62.1 0.038
cholesterol medications (%) 27.7 18.9 0.209
Total cholesterol (mg/dL) 188.3 ± 42.8 196.7 ± 41.0 0.234
energy intake (kcal) 2212.1 ± 870.0 2165.4 ± 775.1 0.732
Protein (g) 108.4 ± 44.5 105.0 ± 36.4 0.594
Potassium (mg) 3676.8 ± 1436.5 3756.2 ± 1245.3 0.719
sodium (mg) 2208.8 ± 1091.8 2204.4 ± 913.5 0.979
Phosphorous (mg) 1665.7 ± 688.0 1604.6 ± 564.2 0.549
Notes: aData are % or mean ± standard deviation. Hypertension was defined as follows: systolic blood pressure (BP) $ 140 mm hg systolic or diastolic BP $ 90 mm hg or 
using antihypertensive treatment. P is considered significant at 0.05.
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Figure  1  Unadjusted  odds  ratios  (OR)  for  microalbuminuria  (MAU)  among 
hypertensive cuban Americans with poor glycemic control.a 
Note: aP is considered significant at 0.05.
Table 2 Likelihood of having microalbuminuria among cuban 
Americans with poor glycemic controla
Parameter  OR  95% CI for OR P value
hypertensive  6.76 1.83 to 25.01 0.004
Normotensive 1.08 0.30 to 3.93 0.899
Notes:  ahypertension  by  glycemic  control  interaction  X2  (1,  n  =  179)  =  4.05, 
P = 0.044. controlled variables included in the logistic regression analysis were 
age, gender, body mass index, known duration of diabetes, total cholesterol levels, 
diabetes and cholesterol medications, smoking, total kcal and protein intakes, and 
intakes of potassium, phosphorous, and sodium. P is considered significant at 0.05. 
Abbreviations: CI, confidence interval; OR, odds ratio.
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Discussion
The results of this study showed that HTN and poor GC are 
major contributors to increasing the likelihood of having 
MAU among Cuban Americans with T2D. The combination 
and/or interaction of these factors over time might increase 
the risk for progression to proteinuria/ESRD and CVD in this 
population. Our findings are supported by the multicenter 
study conducted in Europe that found that the likelihood of 
having MAU increases in patients when HTN and poor GC 
are present along with other coexisting risk factors for CVD.17 
Ravid et al5 reported from their longitudinal study that a 
combination of risk factors, including abnormal BP, plasma 
cholesterol, A1c levels, high BMI, and male gender, identifies 
a group of individuals for poor renal and cardiovascular 
outcomes.
Maintaining adequate BP and GC is an important thera-
peutic goal among individuals with T2D. The UK Prospec-
tive Diabetes Study (UKPDS),18 a longitudinal study with a 
10-year median follow-up, showed that exposure over time 
to hyperglycemia was associated with diabetes complications 
in subjects with T2D. This study also indicated that for every 
1% reduction in A1c level, the risk for microvascular 
complications decreased by 37% and diabetes-related 
death by 21%. A study by Thomaseth et al19 showed that in International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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hypertensive T2D  subjects  with  incipient  diabetic 
nephropathy, both tight BP control and optimal GC delay 
the progression of glomerular filtration rate deterioration. 
Additionally, hypertensive individuals with T2D under tight 
BP control experience a reduction in risk for microvascular 
and macrovascular complications.20
The mechanism and pathways involving MAU with 
diabetic nephropathy and CVD are not fully understood. 
They may be interrelated with endothelial dysfunction and 
inflammation.21 Stehouwer et al22 examined the relationship 
between endothelial dysfunction and inflammation with 
MAU and risk of death in a prospective study among subjects 
with T2D. The results of that study showed that those par-
ticipants with MAU, endothelial dysfunction, and inflamma-
tion had an increased risk in mortality; however, the 
associations of these variables with risk of mortality were 
independent from each other. Hyperglycemia and obesity 
were associated with an increase in markers of endothelial 
dysfunction and inflammation activity,22 possibly indicating 
that the combinations of these factors may be interrelated in 
increasing the risk of death.
The usual course of MAU is progressive; however, not 
all  T2D  individuals  with  MAU  will  develop 
macroalbuminuria. Several authors have documented 
remission and/or regression of MAU in subjects with 
T2D.23–27 Antihypertensive therapy has been shown to 
reduce or slow the progression of diabetic nephropathy. 
In a 6-year prospective study, remission and regression to 
normoalbuminuria were observed in about 50% of T2D 
individuals.23 Other factors independently linked with 
remission and/or regression of MAU were proper BP and 
GC and short duration of MAU. The study by Chan et al24 
with a 5-year mean follow-up of T2D patients with MAU 
treated with angiotensin-converting enzyme (ACE) inhibi-
tor medications showed a 13% reduction in urinary albu-
min excretion (UAE). In addition, the authors pointed out 
the main role that BP and GC play in renal function. 
T2D individuals treated with angiotensin receptor blockers 
(ARBs) (eg, irbesartan and valsatran) experienced a 
38% and 44% reduction in UAE over 2-year and 6-month 
follow-ups, respectively.25,26 Evidence from another pro-
spective study with a 7.8-year follow-up indicated that 
30% of the participants on antihypertensive therapy 
achieved remission to normoalbuminuria.27 Additionally, 
the odds for remission to normoalbuminuria increased in 
these participants with every 1% decrease in A1c level. 
Furthermore, in a study conducted by Mogensen et al,28 
urinary albumin:creatinine ratio was decreased by 50% 
after a 3-month combination treatment with ARB and ACE 
inhibitors in hypertensive T2D individuals with MAU. 
Remission and/or regression of MAU may not only con-
serve renal function but also reduce the risk of CVD.
MAU is one of the earliest clinical signs of renal 
impairment. Testing for MAU has been recommended by the 
ADA in individuals with T2D to be performed at diagnosis 
of diabetes and every year afterwards.29 The ImmunoDip 
dipstick is a rapid and easy screening test to perform, does 
not involve equipment and/or skilled personnel, exhibits a 
high sensitivity, requires only a random urine sample (first 
morning urine is recommended), and has a relatively low cost. 
However, this test does not quantify urinary albumin values 
and requires confirmation with a secondary analysis. This 
method can be used in a physician’s office and/or research 
setting as a first screening tool to detect the presence of MAU. 
The clinical significance of early screening and monitoring 
for MAU is possibly to improve individuals’ prognosis for 
microvascular and macrovascular complications, especially 
among T2D individuals with other concomitant conditions.
Limitations of the study
First, due to the cross-sectional design of the study, single-
voided urine was collected to measure MAU, and we were 
not able to determine the cause–effect relationship between 
the variables. Second, due to the relatively small sample size 
in this study, our sample of Cuban Americans with T2D is 
not representative of the entire Cuban American population 
living in the USA. Nevertheless, to our knowledge, this is 
the first and only study that has examined the relationship 
between MAU, HTN, and GC in this Hispanic subgroup, 
which has an increased risk for T2D and CVD.
Conclusion
Early detection of MAU in this population may provide more 
valuable treatment and improve individuals’ renal and CVD 
outcomes. The therapeutic goals and strategies for MAU 
should focus on preventing long-term complications associ-
ated with T2D, such as kidney and heart diseases. Further 
investigations need to be carried out to fully understand the 
mechanism and absolute CVD risk that an individual with 
T2D has when MAU coexists with other comorbidities.
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